Skip to main content
SpringerLink
Log in

The long-term fate of epistaxis patients with exposure to antithrombotic medication

  • Rhinology
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

The goal of this study was to evaluate independent risk factors for long-term epistaxis recurrences and their severity. Individual retrospective cohort study-2b level of evidence. The medical information of 603 emergency epistaxis patients was acquired during a former study. This cohort has been contacted 6 years later by conventional mail and asked to answer a specific paper questionnaire. The following parameters were evaluated: recurrent epistaxis episodes, need for a surgical intervention to stop the recurrent bleeding, patient’s history for hypertension and diabetes, intake of hemostasis impairing medication now and in the past. One hundred and six (106) patients were included in the study (35.8 % response rate). The mean observation period was 76.58 months. Almost half of the patients (41.5 % = 44/106) reported at least one recurrent epistaxis episode. Patients with exposure to VKA (vitamin K antagonists) showed significantly more frequently a recurrent epistaxis episode. The binary logistic regression confirmed the intake of VKA as an independent and significant risk factor with an odds ratio of 11.6. Every single patient who had to undergo a surgical intervention to stop a recurrent bleeding stated ASA (Acetylsalicylic Acid) intake. We provide evidence that the intake of a vitamin K antagonist is an independent long-term risk factor for recurrent epistaxis episodes. The intake of ASA is a risk factor for the severity of recurrent epistaxis with the increased need for a surgical intervention not only in a short- but also in a long-term perspective.

Level of evidence

This prognostic investigation, designed as a combined prospective and retrospective cohort study, reaches level 2b level of evidence as it includes retrospective aspects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Villwock JA, Jones K (2013) Recent trends in epistaxis management in the United States: 2008–2010. JAMA Otolaryngol Head Neck Surg 139(12):1279–1284

    Article  PubMed  Google Scholar 

  2. Soyka MB, Nikolaou G, Rufibach K, Holzmann D (2011) On the effectiveness of treatment options in epistaxis: an analysis of 678 interventions. Rhinology 49(4):474–478

    CAS  PubMed  Google Scholar 

  3. Verheugt FW, Granger CB (2015) Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet

  4. Melia L, McGarry GW (2011) Epistaxis: update on management. Curr Opin Otolaryngol Head Neck Surg 19(1):30–35

    Article  PubMed  Google Scholar 

  5. Kemal O, Sen E (2014) Does the weather really affect epistaxis? B-ENT 10(3):199–202

    CAS  PubMed  Google Scholar 

  6. Herkner H, Laggner AN, Müllner M, Formanek M, Bur A, Gamper G et al (2000) Hypertension in patients presenting with epistaxis. Ann Emerg Med 35(2):126–130

    Article  CAS  PubMed  Google Scholar 

  7. Soyka MB, Schrepfer T, Holzmann D (2012) Blood markers of alcohol use in epistaxis patients. Eur Arch Oto-Rhino-Laryngol: Off J Eur Fed Oto-Rhino-Laryngol Soc 269(8):1917–1922

    Article  Google Scholar 

  8. Melia L, McGarry G (2008) Epistaxis in adults: a clinical review. Br J Hosp Med (Lond) 69(7):404–407

    Article  Google Scholar 

  9. Soyka MB, Rufibach K, Huber A, Holzmann D (2010) Is severe epistaxis associated with acetylsalicylic acid intake? Laryngoscope 120(1):200–207

    PubMed  Google Scholar 

  10. Kindler RM, Holzmann D, Landis BN, Ditzen B, Soyka MB (2015) The high rate of long-term recurrences and sequelae after epistaxis treatment. Auris Nasus Larynx. doi:10.1016/j.anl.2015.09.011

    PubMed  Google Scholar 

  11. Soyka MB, Holzmann D (2013) Should we test the prothrombin time in anticoagulated epistaxis patients? Allergy Rhinol (Providence) 4(1):e52–e53

    Article  Google Scholar 

  12. Benninger MS, Marple BF (2004) Minor recurrent epistaxis: prevalence and a new method for management. Otolaryngol Head Neck Surg 131(3):317–320

    Article  PubMed  Google Scholar 

  13. Ando Y, Iimura J, Arai S, Arai C, Komori M, Tsuyumu M et al (2014) Risk factors for recurrent epistaxis: importance of initial treatment. Auris Nasus Larynx 41(1):41–45

    Article  PubMed  Google Scholar 

  14. Denholm SW, Maynard CA, Watson HG (1993) Warfarin and epistaxis—a case controlled study. J Laryngol Otol 107(3):195–196

    Article  CAS  PubMed  Google Scholar 

  15. Abrich V, Brozek A, Boyle TR, Chyou PH, Yale SH (2014) Risk factors for recurrent spontaneous epistaxis. Mayo Clin Proc 89(12):1636–1643

    Article  PubMed  Google Scholar 

  16. Tay HL, Evans JM, McMahon AD, MacDonald TM (1998) Aspirin, nonsteroidal anti-inflammatory drugs, and epistaxis. A regional record linkage case control study. Ann Otol Rhinol Laryngol 107(8):671–674

    Article  CAS  PubMed  Google Scholar 

  17. Cingoz F, Oz BS, Arslan G, Guler A, Sahin MA, Gunay C et al (2014) Is chronic obstructive pulmonary disease a risk factor for epistaxis after coronary artery bypass graft surgery? Cardiovasc J Afr 25(6):279–281

    Article  PubMed  PubMed Central  Google Scholar 

  18. Terakura M, Fujisaki R, Suda T, Sagawa T, Sakamoto T (2012) Relationship between blood pressure and persistent epistaxis at the emergency department: a retrospective study. J Am Soc Hypertens 6(4):291–295

    Article  PubMed  Google Scholar 

  19. Lansky AJ, Ng VG, Maehara A, Weisz G, Lerman A, Mintz GS et al (2012) Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. JACC Cardiovasc Imaging 5(3 Suppl):S62–S72

    Article  PubMed  Google Scholar 

  20. Lubianca Neto JF, Fuchs FD, Facco SR, Gus M, Fasolo L, Mafessoni R et al (1999) Is epistaxis evidence of end-organ damage in patients with hypertension? Laryngoscope 109(7 Pt 1):1111–1115

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Zurich USZ, University of Zurich UZH, 8091, Zurich, Switzerland

    Rafael R. Stadler, Rahel Kindler, David Holzmann & Michael B. Soyka

Authors
  1. Rafael R. Stadler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rahel Kindler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Holzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael B. Soyka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael B. Soyka.

Ethics declarations

Conflict of interest

All authors state that there are no conflicts of interest to disclose. There are no financial disclosures.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stadler, R.R., Kindler, R., Holzmann, D. et al. The long-term fate of epistaxis patients with exposure to antithrombotic medication. Eur Arch Otorhinolaryngol 273, 2561–2567 (2016). https://doi.org/10.1007/s00405-016-3913-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-016-3913-9

Keywords

Search

Navigation